Remicade (infliximab) denied as experimental or investigational by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare May Deny Remicade (Infliximab) as Experimental

Remicade (infliximab) has FDA approval for multiple inflammatory conditions, but UnitedHealthcare may issue an "experimental or investigational" denial when the specific indication being treated — or the specific patient population — falls outside the conditions listed in UHC's current coverage policy, even if the use is supported by published clinical evidence and professional society guidelines. This type of denial often occurs when infliximab is used for a relatively newer labeled indication, a pediatric population, or an off-label but guideline-supported condition that UHC has not yet incorporated into its coverage criteria.

## Why This Denial Is Appealable

"Experimental" is one of the most successfully overturned denial categories. Insurers must apply a defined standard — not just internal policy — and if the use is consistent with the conclusions of credible clinical evidence and is accepted in the relevant medical community, the denial is vulnerable on appeal. UHC is required to disclose the specific evidence standard it used and to provide the clinical reviewer's rationale. An appeal supported by a specialist letter and references to applicable guidelines from the relevant professional society (such as the ACR, AGA, or ECCO, as appropriate to the condition) has strong grounds.

## Federal Appeal Framework

• Internal appeal: ACA §2719 and ERISA §503 require a full-and-fair internal review. UHC must identify the specific criteria that led to the "experimental" classification and allow you to respond to them.
• External review: Experimental/investigational denials are specifically subject to independent external review. An accredited external reviewer will evaluate whether the use is consistent with generally accepted medical evidence — applying a standard independent of UHC's policy. File within approximately four months of the final internal denial.
• Expedited review: Available when the patient's condition is urgent. Request simultaneously with the standard appeal.

## Documentation to Gather

1. FDA-approved prescribing information — if the use is on-label, attach the current label and highlight the applicable indication. If the use is off-label, this document supports the mechanism and safety profile. 2. Relevant professional society guidelines — a letter or attachment referencing the applicable guideline organization (e.g., the relevant gastroenterology, rheumatology, or dermatology society) and confirming the use is endorsed in current guidance. 3. Prescriber specialist letter — from the treating specialist, stating the diagnosis, the clinical evidence supporting this use, and why infliximab is medically necessary for this patient. 4. Published clinical evidence summary — a brief summary (prepared by the prescriber or their office) of the peer-reviewed evidence base for this use, without fabricated statistics; cite article titles and journals, not specific numbers.

## Criteria-Mapping Structure

| UHC "Experimental" Criterion (copy verbatim from denial) | Evidence Response | |---|---| | Definition of experimental as stated in policy | How this use meets the "accepted medical practice" standard | | Evidence standard applied (e.g., compendia, peer-reviewed literature) | Specific sources satisfying that standard | | Any coverage exception pathway in policy | Corresponding clinical documentation |

Request the clinical reviewer's full rationale and the specific evidence standard applied. That disclosure is required and often reveals the exact gap you need to close in your appeal.